• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.

作者信息

Tatu-Chitoiu Gabriel, Teodorescu Cristina, Dan Monica, Capraru Petre, Guran Manuela, Istratescu Oana, Tatu-Chitoiu Alexandrina, Bumbu Aurelia, Dorobantu Maria

机构信息

Clinic of Cardiology, Emergency Hospital/Outpatient Clinic, Calea Floreasca nr. 8 sector 1, 79406 Bucharest, Romania.

出版信息

J Thromb Thrombolysis. 2003 Jun;15(3):171-9. doi: 10.1023/B:THRO.0000011372.26594.01.

DOI:10.1023/B:THRO.0000011372.26594.01
PMID:14739626
Abstract

OBJECTIVE

To compare a new streptokinase regimen combined with either enoxaparin or unfractionated heparin (UFH) and the traditional streptokinase regimen combined with UFH in patients with acute myocardial infarction (AMI).

METHODS

412 patients (<75 years), hospitalized within 6 hours of the onset of chest pain, were allocated thrombolytic therapy by the treating physician: streptokinase 0.75 MU/10 minutes, repeated if no coronary reperfusion after one dose, plus enoxaparin 40 mg intravenously followed by 1 mg/kg bodyweight subcutaneously at 12-hour intervals for 5-7 days (n = 102); the same streptokinase regimen plus UFH 1000 IU/60 minutes intravenously for 48-72 hours ( n = 106); or streptokinase 1.5 MU/60 minutes plus the same UFH regimen (n = 204). All patients received 250-325 mg aspirin/day. Coronary reperfusion rates, 30-day mortality and hemorrhagic complications were recorded.

RESULTS

Coronary reperfusion rates with 0.75 streptokinase + enoxaparin (78.4%) and 0.75 streptokinase + UFH (74.5%) were significantly higher than those with 1.5 streptokinase + UFH (62.2%), but there was no significant difference between the groups receiving the new regimen. Overall 30-day mortality (6.3%) was significantly lower than with 1.5 streptokinase + UFH (12.7%) ( p = 0.037). The incidence of major and minor hemorrhagic events was similar in all groups.

CONCLUSIONS

The accelerated streptokinase regimen was well tolerated and resulted in a significantly higher coronary reperfusion rate and significantly lower mortality compared with the traditional regimen. The 0.75 streptokinase + enoxaparin combination was at least as efficacious as the 0.75 streptokinase + UFH combination and is preferred because of its ease of administration and predictable anticoagulant effect.

摘要

相似文献

1
Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.
J Thromb Thrombolysis. 2003 Jun;15(3):171-9. doi: 10.1023/B:THRO.0000011372.26594.01.
2
Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study).加速使用链激酶和依诺肝素治疗ST段抬高型急性心肌梗死(ASENOX研究)
Kardiol Pol. 2004 May;60(5):441-6.
3
Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.0.75MU链激酶双推注联合依诺肝素与负荷剂量阿替普酶联合普通肝素治疗ST段抬高型心肌梗死的对比研究
Rom J Intern Med. 2003;41(4):395-408.
4
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).链激酶诱发的低血压对急性心肌梗死溶栓治疗的患者没有不利影响。罗马尼亚急性心肌梗死加速链激酶研究(ASK-ROMANIA)的一项子研究。
Rom J Intern Med. 2004;42(3):557-73.
5
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.链激酶和依诺肝素作为基于纤维蛋白特异性溶栓方案的替代方案:ExTRACT-TIMI 25分析
Drugs. 2009 Jul 30;69(11):1433-43. doi: 10.2165/00003495-200969110-00003.
6
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).低分子量肝素依诺肝素与普通肝素辅助重组组织型纤溶酶原激活剂溶栓及阿司匹林的随机对照研究:肝素与阿司匹林再灌注治疗(HART II)的第二项试验。
Circulation. 2001 Aug 7;104(6):648-52. doi: 10.1161/hc3101.093866.
7
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.替奈普酶与低分子量肝素依诺肝素或普通肝素联合用于院前环境的疗效和安全性:急性心肌梗死新溶栓方案安全性和有效性评估(ASSENT)-3 PLUS随机试验
Circulation. 2003 Jul 15;108(2):135-42. doi: 10.1161/01.CIR.0000081659.72985.A8. Epub 2003 Jul 7.
8
Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.未接受再灌注治疗的ST段抬高型心肌梗死患者使用普通肝素与氯吡格雷联合治疗。
Atherosclerosis. 2015 Jul;241(1):151-6. doi: 10.1016/j.atherosclerosis.2015.04.794. Epub 2015 Apr 27.
9
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.替奈普酶与依诺肝素、阿昔单抗或普通肝素联合使用的疗效和安全性:急性心肌梗死的ASSENT-3随机试验
Lancet. 2001 Aug 25;358(9282):605-13. doi: 10.1016/S0140-6736(01)05775-0.
10
[Application of enoxaparin simultaneously with fibrinolysis in patients with acute myocardial infarction with ST-elevation].依诺肝素与纤溶疗法同时应用于ST段抬高型急性心肌梗死患者
Med Pregl. 2009 Jan-Feb;62(1-2):13-6. doi: 10.2298/mpns0902013d.

引用本文的文献

1
Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen.ST段抬高型心肌梗死患者的纤溶治疗:加速与标准链激酶输注方案对比
J Cardiovasc Thorac Res. 2017;9(4):209-214. doi: 10.15171/jcvtr.2017.36. Epub 2017 Dec 30.

本文引用的文献

1
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.
Eur Heart J. 2002 Aug;23(16):1282-90. doi: 10.1053/euhj.2001.3083.
2
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.急性心肌梗死溶栓治疗后依诺肝素与普通肝素的随机对照比较。
Eur Heart J. 2002 Apr;23(8):627-32. doi: 10.1053/euhj.2001.2940.
3
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.依诺肝素作为ST段抬高型心肌梗死的辅助抗凝血酶治疗:心肌梗死溶栓(TIMI)23试验的结果
Circulation. 2002 Apr 9;105(14):1642-9. doi: 10.1161/01.cir.0000013402.34759.46.
4
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.在心肌梗死溶栓治疗(TIMI)11B和心肌梗死溶栓治疗II期(ESSENCE)试验的1年随访中,依诺肝素在预防临床事件方面优于普通肝素。
Eur Heart J. 2002 Feb;23(4):308-14. doi: 10.1053/euhj.2001.2779.
5
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.急性心肌梗死接受纤溶治疗患者中比伐卢定与肝素的凝血酶特异性抗凝治疗:HERO-2随机试验
Lancet. 2001 Dec 1;358(9296):1855-63. doi: 10.1016/s0140-6736(01)06887-8.
6
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.替奈普酶与依诺肝素、阿昔单抗或普通肝素联合使用的疗效和安全性:急性心肌梗死的ASSENT-3随机试验
Lancet. 2001 Aug 25;358(9282):605-13. doi: 10.1016/S0140-6736(01)05775-0.
7
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).低分子量肝素依诺肝素与普通肝素辅助重组组织型纤溶酶原激活剂溶栓及阿司匹林的随机对照研究:肝素与阿司匹林再灌注治疗(HART II)的第二项试验。
Circulation. 2001 Aug 7;104(6):648-52. doi: 10.1161/hc3101.093866.
8
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.急性心肌梗死的再灌注治疗:采用纤溶疗法或联合降低纤溶疗法及血小板糖蛋白IIb/IIIa抑制作用的治疗——GUSTO V随机试验
Lancet. 2001 Jun 16;357(9272):1905-14. doi: 10.1016/s0140-6736(00)05059-5.
9
The search for replacements for unfractionated heparin.
Circulation. 2001 May 8;103(18):2310-4. doi: 10.1161/01.cir.103.18.2310.
10
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.肝素与低分子量肝素:作用机制、药代动力学、给药剂量、监测、疗效及安全性
Chest. 2001 Jan;119(1 Suppl):64S-94S. doi: 10.1378/chest.119.1_suppl.64s.